REDWOOD CITY, Calif.,
Nov. 3, 2015 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced that
members of its management team will present at the following
conferences in November:
- Brad Cole, chief operating officer and chief financial officer,
will present at the 24th Annual Credit Suisse Healthcare
Conference in Phoenix, Ariz. on
Tuesday, November 10 at 4:30 p.m. Mountain Standard Time (MST); and
- Kim Popovits, chairman of the board, chief executive officer
& president, will present at the Canaccord Genuity 2015 Medical
Technology and Diagnostics Forum in New
York on Thursday, November 19
at 1:00 p.m. Eastern Standard Time
(EST).
To access the live and subsequently archived webcast of the
presentations, go to the Investor Relations section of
the company's web site at
http://investor.genomichealth.com. Please connect to the web
site at least 15 minutes prior to the call to allow for any
software download that may be necessary.
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer tests
applies advanced genomic science to reveal the unique biology of a
tumor in order to optimize cancer treatment decisions. With half a
million patients tested in more than 90 countries, the Oncotype DX
tests have redefined personalized medicine by making genomics a
critical part of cancer diagnosis and treatment. To learn more
about OncotypeDX tests, visit: www.OncotypeDX.com,
www.mybreastcancertreatment.org and
www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that address both the overtreatment and optimal
treatment of early-stage cancer, one of the greatest issues in
healthcare today. The company is applying its world-class
scientific and commercial expertise and infrastructure to lead the
translation of massive amounts of genomic data into
clinically-actionable results for treatment planning throughout the
cancer patient's journey, from diagnosis to treatment selection and
monitoring. The company is based in Redwood
City, California, with international headquarters
in Geneva, Switzerland. For more information, please
visit, www.GenomicHealth.com and follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits of the test to
physicians, patients and payors. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the ability of test
results to change treatment decisions; the risks and uncertainties
associated with the regulation of the company's tests; the results
of clinical studies; the applicability of clinical study results to
actual outcomes; the risk that the company may not obtain or
maintain sufficient levels of reimbursement, domestically or
abroad, for its existing tests and any future tests it may develop;
the risks of competition; unanticipated costs or delays in research
and development efforts; and the other risks set forth in the
company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on
Form 10-Q for the quarter ended June 30, 2015. These
forward-looking statements speak only as of the date
hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-to-present-at-two-upcoming-investor-conferences-300168434.html
SOURCE Genomic Health, Inc.